Fosun Pharma Invests RMB 414 Million in Hepatology-Focused Nucleic Acid Therapeutics Biotech Xingyao Kunze, Which Files IPO Prospectus
Hepa Thera
Innovative Drug Developer in the Field of Hepatology
JD Health
Internet Medical and Health Service Platform Provider
May 26, 2026,Fosun Pharma announced that 12 new investors, including its controlling subsidiary Fosun Pharma Industry, have jointly signed the 《Capital Increase and Share Transfer Agreement》 with Hepa Thera and its existing shareholders. The agreement stipulates, among other things, that: (1) the 12 new investors intend to contribute capital to participate in Hepa Thera's Series B financing, subscribing to a total of RMB 5.305838 million in newly increased registered capital (i.e., the “Series B Financing”); and (2) six of these new investors further intend to contribute capital to acquire a total of RMB 3.768613 million in the target company's existing registered capital held by the transferors (namely, the Suzhou Fund and the Tianjin Fund) (i.e., the “Equity Transfer”).Specifically, Shanghai Fosun Pharmaceutical Development Co., Ltd. intends to invest approximately RMB 218 million to subscribe for RMB 2.936752 million of the newly increased registered capital of the Target Company, and intends to invest approximately RMB 196.6 million to acquire from the transferor a total of RMB 3.086511 million of the existing registered capital of the Target Company. On the same day, the new investor, Hepa Thera, and its existing shareholders jointly signed the 《Shareholders' Agreement》.
E.N.D
